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Protocol
AbstrACt
Introduction Previous reviews indicate that the effect 
of acupuncture on stable angina pectoris (SAP) remains 
controversial. The results of trials published in the past 
5 years may possibly change this situation, but an updated 
systematic review is not available. We therefore designed 
this study to systematically assess the efficacy and safety 
of acupuncture for treating SAP.
Methods and analysis Nine online databases will 
be searched without language or publication status 
restrictions from their inception to September 2017. 
Randomised controlled trials that include patients with 
stable angina receiving acupuncture therapy versus a 
control group will be deemed eligible. The selection of 
studies, data extraction and risk of bias assessment 
will be carried out by two independent reviewers. Data 
synthesis will be performed using RevMan V.5.3 software 
with either a fixed effects model or random effects model, 
depending on the heterogeneity test. Evidence quality 
will be evaluated using the Grading of Recommendations 
Assessment, Development and Evaluation system. The 
efficacy–effectiveness spectrum for each included trial 
will be rated using the Rating of Included Trials on the 
Efficacy-effectiveness Spectrum tool. Outcomes of interest 
include the improvement of weekly angina attacks and 
reduction of nitroglycerin medication use after receiving 
acupuncture treatment, the incidence of cardiovascular 
events, heart rate variability, pain intensity measured on a 
visual analogue scale, total workload and exercise duration 
at peak exercise, safety and adverse events. A meta-
analysis will be conducted if no considerable heterogeneity 
is detected. The results will be presented as risk ratios 
with 95% CIs for dichotomous data and weighted mean 
differences or standardised mean differences with 95% 
CIs for continuous data.
Ethics and dissemination This systematic review will not 
involve private information from individuals or endanger 
their rights, and therefore does not necessarily require 
ethical approval. The results may be published in a peer-
reviewed journal or disseminated in relevant conferences.
trial registration number CRD42015016201.
bACkground
Stable angina pectoris (SAP) is a prevalent 
cardiovascular disease that greatly compro-
mises a patient’s life quality and longevity. It 
is a clinical syndrome involving temporary 
hypoxic myocardial ischaemia and features 
sensations of burning, severe pain, pressure 
and other forms of discomfort in the left 
anterior chest region. In the USA, SAP affects 
more than 7.8 million people and is reported 
to have an incidence of more than 0.5 million 
cases per year.1 In the European population, 
its incidence is estimated to be 10%–20% of 
people aged 65–74 years.2 Within China, the 
prevalence is 2.4% among men and 3.2% 
among women,3 which makes it a serious 
public health problem. According to the 
2013 European Society of Cardiology guide-
lines on the management of stable coronary 
artery disease,4 current treatment options 
for SAP are diverse, generally including life-
style modification and elimination of risk 
factors, pharmacological management and 
revascularisation.
Although many therapeutic interventions 
are available to patients, the management of 
SAP is not satisfactory. Most patients continue 
to suffer from SAP or the side effects of their 
medications.5 Non-pharmacological ther-
apies as secondary options are frequently 
chosen by patients. Acupuncture, a major 
component of traditional Chinese medicine, 
has been extensively used by clinicians for the 
management of acute attacks and for prophy-
laxis of SAP since ancient times.6 7 The clin-
ical practice of acupuncture involves a series 
of procedures that entail the insertion of fili-
form needles into designated acupuncture 
strengths and limitations of this study
 ► Although systematic reviews of acupuncture for sta-
ble angina pectoris have been conducted previously, 
this study will update the evidence base by including 
many clinical trials that have been published in the 
past 5 years.
 ► Rating the efficacy–effectiveness spectrum of trials 
included in the systematic review has the potential 
to indicate how close current evidence is to ‘re-
al-world’ practice.
 ► As several clinical outcomes have been used in pub-
lished trials, a pooled analysis of all included studies 
may not be possible; however, subgroup analyses 
will be performed according to different outcomes.
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points, followed by different needle manipulation tech-
niques. Clinical observations and expert opinions suggest 
that acupuncture has the potential to reduce disease dura-
tion, angina attack frequency and nitroglycerin consump-
tion, and improve cardiac work capacity.8–11 Studies 
suggest that acupuncture may exert a myocardial protec-
tion and vascular dilation effect against cardiac ischaemia 
and reperfusion by inhibiting the beta (1)-adrenoceptor 
signalling pathway and regulating myocardial enzyme 
action.12–17 Therefore, acupuncture has the potential to 
be an effective supplementary treatment option for SAP.
However, the effect of acupuncture for SAP is still 
controversial from the perspective of evidence-based 
medicine. Several systematic reviews have been conducted 
to assess the clinical benefits of acupuncture therapy for 
SAP, but all of them, including the most recent, which 
reviewed studies before 2013, were inconclusive due 
to poor-quality trials.18–20 Recently, it has been noticed 
with great interest that a rough estimation of at least 
10 clinical studies has been published or conducted in 
the past 5 years.6 21–29 These studies have great potential 
to change the current evidence base of acupuncture for 
SAP. However, at present there exists no updated system-
atic review or study protocol published on this question. 
We thus have a unique opportunity to re-evaluate the 
issue and conceive this systematic review to determine the 
effectiveness and safety of acupuncture for patients with 
SAP based on the most comprehensive and up-to-date 
resources.
MEthods
Criteria for including studies in the review
Types of studies
The review will include randomised controlled trials 
(RCT) that were reported in any language. Completed 
and ongoing trials will be included. Trials using a two-arm 
or three-arm parallel design will be included. Crossover 
trials and quasi-RCTs will be excluded. Any study with 
a sample size of less than 10 participants will also be 
excluded from this review.
Types of participants
Trials including participants who meet the diagnostic 
criteria of SAP or stable coronary heart disease will 
be included.30–33 All eligible study participants will be 
included in this review regardless of their age, race or 
gender. Trials including study participants who are not 
appropriate to receive acupuncture therapy, such as preg-
nant or lactating women and those with additional severe 
diseases, will be excluded.
Types of interventions
The interventions considered in the studies must involve 
needle insertion at acupuncture points, pain points or 
trigger points, and be described as acupuncture. Adjunct 
therapy with acupuncture that is additive to the active 
treatment will be included in this review. However, other 
methods of stimulating acupuncture points without 
needle insertion (such as moxibustion, laser stimulation, 
massage or transcutaneous electrical nerve stimulation) 
will be excluded. Studies that compare the efficacy of 
different forms of acupuncture will be excluded as this is 
not the focus of the review.
Types of comparator(s)/control
The following control groups will be considered:
1. Acupuncture versus sham devices (interventions mim-
icking ‘verum’ acupuncture/treatment, but deviating 
in at least one aspect considered important by acu-
puncture theory, such as skin penetration or non-acu-
point location).
2. Acupuncture versus routine care.
3. Acupuncture versus conventional drugs.
4. Acupuncture in addition to active treatment versus ac-
tive treatment alone.
Studies that only compare different forms of acupunc-
ture or compare acupuncture with other complemen-
tary and alternative therapeutic interventions shall be 
excluded.
Types of outcome measures
Primary outcomes
The number of weekly angina attacks and nitroglyc-
erin use during a period of at least 2 weeks following 
randomisation.
Secondary outcomes
1. Cardiovascular events.
2. ECG changes (mainly ST-segment depression).
3. Heart rate variability.
4. Angina pain intensity (assessed by visual analogue 
scale).
5. Affective emotions (assessed by self-rating anxiety 
scale and self-rating depression scale).
6. Total workload (in Met-minutes) and exercise dura-
tion (in seconds) at peak exercise.
7. Overall tolerability.34
8. Overall acceptability.34
search methods for identification of studies
Electronic searches
The following databases will be searched from their 
inception to September 2017: MEDLINE, Ovid, EMBASE, 
Cochrane Library, the Allied and Complementary Medi-
cine Database (AMED), Chinese National Knowledge 
Infrastructure (CNKI), Chinese Biomedical Literature 
Database (CBM), Wanfang Database, the Chongqing VIP 
Chinese Science and Technology Periodical Database 
(VIP). Only RCTs that evaluate the effect of acupunc-
ture in comparison with the aforementioned compar-
ator controls will be included. There will be no language 
restriction on the included trials. The following medical 
search headings (MeSH) will be used: stable angina 
pectoris, stable angina, angina pectoris, angina, acupunc-
ture, acupuncture therapy, electroacupuncture, elec-
troacupuncture therapy, manual acupuncture, acupoint, 
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randomised controlled trial, randomised controlled, 
randomised, controlled, clinical trial, comparative 
study, prospective study. Chinese translations of these 
search terms will be used for the Chinese databases. 
The searching strategy for MEDLINE is listed in table 1. 
The search strategy will be modified according to the 
Cochrane Handbook for Systematic Reviews35 for other 
databases.
Searching other resources
Ongoing trials with unpublished data will be retrieved 
from the following clinical trial registries: the NIH clin-
ical registry  ClinicalTrials. gov (https://www. clinicaltrials. 
gov/), the International Clinical Trials Registry Platform 
(ICTRP) (http://www. who. int/ ictrp/ en/), the Austra-
lian New Zealand Clinical Trials Registry (http://www. 
anzctr. org. au/) and the Chinese clinical registry (http://
www. chictr. org/ en/). The list of all identified publica-
tions including relevant systematic reviews and meta-anal-
yses will be reviewed to further identify additional trials. 
Useful but incomplete data will be obtained for data 
synthesis from the contact trial personnel.
data collection and analysis
Selection of studies
The search results will be imported from the original 
databases to Endnote V.X7.1. Two reviewers (MY and MS) 
will independently assess the eligibility of the retrieved 
studies according to the inclusion criteria. For prelim-
inary study selection, only the title and abstract will be 
reviewed to exclude obviously inappropriate publications. 
Unmatched studies will be removed to a trash box in the 
software. The reasons for exclusion will be recorded as an 
Excel data set. The next step will be to further evaluate 
the included studies by reading their full-text version. 
The reference list will be checked by the two reviewers 
to identify potentially missing trials. The selection results 
will be cross-checked by the two reviewers. Any disagree-
ment will be resolved by consensus. Further argument will 
be arbitrated by a third reviewer (TD). Each eligible trial 
will be assigned a study ID formatted as follows: surname 
of the first author + space + year of publication (eg, Yang 
2017).
Data extraction and management
Two reviewers (HL and ZS) will independently double-
check the eligibility of the included studies and extract 
data by entering details into a predefined data acquisi-
tion form. This acquisition form will include four main 
domains: citation information (title, author list, source 
of publication, year of publication, first author’s name 
and affiliation, country, sponsor), design (design, partici-
pants, trial methods, duration, intervention details, care-
giver information), results (outcome measures, adverse 
events) and conclusion. Any discrepancy noticed in the 
process of data cross-checking will be resolved through 
discussion and the suggestion of a third reviewer (LL).
Assessment of risk of bias in included studies
The risk of bias for each included trial will be evaluated 
using the Cochrane Collaboration’s tool for assessing risk 
of bias in randomised trials.36 Two reviewers (MY and 
TD) will input the relevant details of each trial into the 
RevMan software37 (V.5.3) and assess the trial for at least 
six domains (random sequence generation, allocation 
concealment, blinding of participants and personnel, 
blinding of outcome assessment, incomplete outcome 
data, selective reporting and other bias if necessary). For 
each domain, the trial will be rated as high, unclear or low 
risk of bias. A trial that is rated high risk of bias in one or 
more domains will be rated as ‘high risk’, while a low risk 
of bias in all domains will be rated as ‘low risk’. If there is 
low or unclear risk of bias for all key domains, the trial will 
be rated as ‘unclear risk’.36 The contact person or corre-
sponding author will be contacted if basic information is 
missing for the risk of bias assessment. The rating results 
will be cross-checked and discrepancies resolved through 
discussions and the arbitration of a third reviewer (FL).
Table 1 Search strategy in MEDLINE
#1 randomized controlled trial [pt]
#2 controlled clinical trial [pt] 
#3 randomized [tiab] 
#4 placebo [tiab] 
#5 clinical trials as topic [mesh: noexp] 
#6 randomly [tiab] 
#7 trial [ti] 
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 
#9 animals [mh] NOT humans [mh] 
#10 #8 NOT #9 
#11 angina, stable [mesh] 
#12 chronic stable angina pectoris [tiab] 
#13 stable angina pectoris [tiab] 
#14 chronic stable angina [tiab] 
#15 stable angina [tiab] 
#16 angina pectoris [ti] 
#17 angina [ti] 
#18 #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 
#19 acupuncture [mesh] 
#20 acupuncture therapy [mesh] 
#21 electroacupuncture [tiab] 
#22 electroacupuncture therapy [tiab] 
#23 manual acupuncture [tiab] 
#24 dry needle [tiab] 
#25 acupoint [tiab] 
#26 #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 
#27 #10 AND #18 AND #26 
#28 remove duplicates from #27 
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Measures of treatment effect
Efficacy data will be synthesised and statistically analysed 
in RevMan V.5.3. Dichotomous data will be analysed by 
using a risk ratio with 95% CIs. For continuous outcomes, 
data will be analysed by using a weighted mean difference 
(WMD) or a standard mean difference (SMD) with 95% 
CIs. The WMD will be used for the same scale or same 
assessment instrument; SMD will be used for different 
assessment tools.
Unit of analysis issues
The units of each outcome from different trials will be 
converted to the International System of Units before 
statistical analysis.
Dealing with missing data
Whether the data were missing on purpose or ‘at 
random’ will be predetermined by contacting the corre-
sponding author or relevant author. Available data will 
be analysed following confirmation by investigators that 
the data were missing ‘at random’.35 If not, a request 
for missing data will be sent to the original investigators 
of the trial, or the contact person recorded in the trial 
registry. In case of no reply from the authors or contact 
person, we will impute the missing data with replacement 
values, treating these as if they were observed. The last 
observation carried forward imputation method will be 
used to assume a missing value and then an intention-to-
treat analysis will be performed. Moreover, if possible, we 
will perform sensitivity analyses to assess how sensitive the 
results are to reasonable changes in the assumptions that 
are made. The potential impact of the effect of missing 
data on the final findings of the review will be addressed 
in the discussion.
Assessment of heterogeneity
Χ2 tests will be performed in the forest plot using 
RevMan V.5.3 to investigate the statistical heteroge-
neity and a p value of less than 0.10 will be considered 
significant, in line with the Cochrane Handbook.35 
Moreover, the I2 value will be calculated to quan-
tify the impact of the statistical heterogeneity on the 
meta-analysis. The Cochrane Handbook classifies the 
I2 values into four categories: 0%–40%, might not be 
important; 30%–60%, indicates moderate heteroge-
neity; 50%–90%, represents substantial heterogeneity; 
75%–100%, suggests considerable heterogeneity.
Assessment of reporting biases
A funnel plot will be generated to observe the reporting 
bias when more than 10 trials are included.35
Data synthesis
Clinical data will be imported into RevMan software 
(V.5.3) to perform data synthesis. Data will be synthe-
sised and analysed depending on the level of statistical 
heterogeneity. If the heterogeneity tests show little or no 
statistical heterogeneity in these trials, the fixed effects 
model will be used for the pooled data. If significant 
heterogeneity is detected (if the I2 value is no less than 
50%), the random effects model will be used for data 
synthesis. If there is considerable heterogeneity in the 
trials, meta-analysis will not be performed. In this case, 
we will try to identify the source of heterogeneity from 
both clinical and methodological aspects and a narrative, 
qualitative summary will be provided.
Subgroup analysis and investigation of heterogeneity
If data are available, a subgroup analysis will be conducted 
according to variations in the characteristics of the trial 
participants and acupuncture treatments. When consid-
erable heterogeneity is detected in a previous analysis, a 
subgroup analysis will be performed if necessary.
Sensitivity analysis
Sensitivity analysis will be used to monitor the robustness 
of the primary decision made in the review process. We 
will consider several decision nodes within the process 
of the systematic review to implement a sensitivity review, 
such as small studies, methodological weaknesses and 
missing data. The sensitivity analysis will involve two steps, 
as suggested by the Cochrane Handbook: first, including 
all studies as the primary meta-analysis does and second, 
including those that are definitely known to be eligible. 
The results of the sensitivity analysis will be presented in 
summary tables. The risk of bias in the review process, as 
indicated by the results of the sensitivity analysis, will be 
discussed.
Other analysis
Consideration will be given to using a metaregression 
analysis to investigate the impact of the year of publica-
tion on the outcome estimates.
Evidence quality evaluation
The reviewers will use the online Grading of Recom-
mendations Assessment, Development and Evaluation 
(GRADE) application, GRADEpro (https:// gradepro. 
org/), to independently assess the quality of evidence 
for each outcome.38 Evidence quality will be rated 
‘high’, ‘moderate’, ‘low’ or ‘very low’ according to the 
GRADE rating standards.39 40 The quality of evidence 
of a specific study will be assessed according to the 
appropriateness of the study design, soundness of 
implementation, directness and precision of evidence, 
consistency or homogeneity of the results and other 
biases. A summary of findings table will be generated 
and included in the final report.
Efficacy–effectiveness spectrum analysis
Because systematic reviews can include both explanatory 
trials and pragmatic trials for data synthesis, it is important 
for clinicians and researchers to know the nature of the 
evidence. Therefore, to analyse the efficacy–effectiveness 
spectrum of each included trial, the Rating of Included 
Trials on the Efficacy-effectiveness Spectrum scale41 will 
be used. Four domains will be assessed to justify the effi-
cacy–effectiveness spectrum for each trial: participant 
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characteristics, trial setting, flexibility of interventions 
and clinical relevance of interventions.
Ethics and dissemination
This review will not involve private information from 
individuals or compromise their rights, and therefore 
does not require ethical approval. The results may be 
published in a peer-reviewed journal or disseminated 
at relevant conferences. Due to the paucity of related 
publications in the field, this review article will, by 
adding more recent studies into the analysis, provide 
more robust evidence of acupuncture therapy for 
treating stable angina, and lead to informed clinical 
practice and acupuncture research.
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